Allianz Asset Management Gmb H Ventyx Biosciences, Inc. Transaction History

Allianz Asset Management Gmb H

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2023 Nov 13, 2023	SELL	$29.8 - $40.3 $172,840 - $233,739	-5,800 Reduced 25.89%	16,600 $576,000
Q2 2023 Aug 11, 2023	BUY	$28.53 - $39.55 $639,072 - $885,919	22,400 New	22,400 $734,000

127

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $110M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.